For example, several studies have shown clinically meaningful responses following treatment of patients bearing head and neck squamous cell carcinoma (HNSCC) with antibodies to programmed death receptor-1 (PD-1) [1,2]. The gene discussed is PDCD1; the disease is head and neck squamous cell carcinoma.